April 4, 2024
Taisho Pharmaceutical said on April 3 that vornorexant (TS-142), an orexin receptor antagonist it is currently developing in Japan, delivered favorable results in a domestic PIII trial for the treatment of insomnia. The investigational drug showed significant improvements versus placebo...read more